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Abstract
Cytomegalovirus (CMV) infection represents one of the main cause mortality after Stem
Cell Transplantation. Recently, a protective effect of the T allele of rs12979860 IL28B Single
Nucleotide Polymorphisms (SNPs) against CMV infection in the allogenic stem cell trans-
plantation was suggested. We investigate whether the rs12979860 IL28B SNP and the rela-
tive rs368234815 (IFNλ4) genotype may affect the incidence of active CMV infection in
Autologous stem cell transplantation (Auto-SCT) setting. The study included 99 patients
who underwent to Auto-SCT. IL28 and IFNΔ4 SNPs were correlated with CMV reactivation
along with other clinical and treatment parameters. CMV reactivation by CMV DNAemia
was evaluated once a week until day 100 from Auto-SCT. CMV reactivation was docu-
mented in 50% (TT-ΔG/ΔG), 35% (CC-TT/TT) and 29.2% (CT-TT/ΔG) of the patients
respectively. No differences in CMV copies number were recorded at reactivation between
different IL28/IFNλ4 genotypes. The analysis of patients older than 60 years showed a sig-
nificantly higher incidence of active CMV infection in the TT-ΔG/ΔG (83%) population with
respect to CC-TT/TT (21%) and CT-TT/ΔG (40%) patients. Our data suggest a negative
role of TT-ΔG/ΔG genotype in the CMV reactivation in Auto-SCT. The exposure to rituximab
and the pre-infusion presence of anti CMV IgG also significantly influenced CMV
reactivation.
Introduction
Cytomegalovirus (CMV) infection represents one of the main cause of morbidity and mortal-
ity after stem cell transplantation (SCT) because the deep immunosuppression contributes
PLOS ONE | https://doi.org/10.1371/journal.pone.0200221 July 23, 2018 1 / 11
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Annibali O, Piccioni L, Tomarchio V,
Circhetta E, Sarlo C, Franceschini L, et al. (2018)
Impact of IFN lambda 3/4 single nucleotide
polymorphisms on the cytomegalovirus
reactivation in autologous stem cell transplant
patients. PLoS ONE 13(7): e0200221. https://doi.
org/10.1371/journal.pone.0200221
Editor: Massimo Ciccozzi, National Institute of
Health, ITALY
Received: March 19, 2018
Accepted: June 21, 2018
Published: July 23, 2018
Copyright: © 2018 Annibali et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
significantly to the loss of CMV-specific adaptive immune control [1]. Thus, the role of the
innate immunity to control CMV replication is magnified in transplant setting. Type III inter-
ferons IFNs), including IFNλ1, IFNλ2 and IFNλ3 also known as IL29, IL28A and IL28B
respectively, are thought to display antiviral and immunomodulatory properties in vivo, which
may partially overlap those exerted by type I IFNs. [2–3] Type I and Type III IFNs both gener-
ate an antiviral state by triggering the JAK-STAT pathway, ultimately upregulating the expres-
sion of IFN stimulated genes. [2–3]. The rs12979860 IL28B single nucleotide polymorphism
(SNP) is well known to influence the spontaneous and treatment-induced clearance in HCV
infection [4–9]. However, attempts to identify a functional mechanism linked to IL-28B SNPs
have failed to yield consistent results. Recently, Prokunina-Olsson et al. [10] pinpoint a dinu-
cleotide rs368234815 frameshift variant (previously named ss469415590 TT/ΔG) that is
upstream of and in the same orientation as IL28B able to generate a novel IFNλ protein, called
IFNλ4. Individuals who carry the homozygosis for the minor ΔG allele of the ss469415590 var-
iant ΔG/ΔG genotypes) can produce IFNλ4, whereas the presence of the major TT allele leads
to a frameshift in exon 1 and disrupts the IFNλ4 open reading frame. Linkage disequilibrium
(LD) between IFNλ4-ΔG, which creates IFNλ4 protein, and the (unfavorable) IFNλ3
rs12979860-T allele was demonstrated to be very high among Caucasians (>0.9) [10]. This
means that these variants are always inherited together making sometime difficult to deter-
mine which one is more strongly associated with the outcome and, therefore, more likely to be
causal. Thus, the “so called” unfavorable rs12979860 TT genotype co-migrates with the ΔG/ΔG
IFNλ4 type and is itself strictly associated with the production of the IFNλ4 protein. Despite
there is strong evidence that genotypes for rs12979860 and IFNλ4- TT/ΔG may play a role in
other infections [11–16], their relevance in CMV reactivation following stem cell transplanta-
tion is still debated. Several lines of evidence suggest that IL28B/IFNλ4 SNPs might play a role
in the control of CMV infection in Allo-SCT and solid organ cells transplant recipients
[1,17,18]; however, to date no data are available in autologous stem cells transplantation
(Auto- SCT) setting. The current study was aimed at investigating factors that may be involved
in CMV reactivation and whether the rs12979860 IFNλ3 polymorphism and the relative
rs368234815 IFNλ4 genotype may have any effect on the incidence rate and outcome of active
CMV infection in Auto-SCT.
Methods
This study was approved by Campus Bio-Medico ethical committee (n.02.15TS.
COMETCBM).All patients included in this study provided written, informed consent.
Patients
Starting from October 2014, 99 consecutive patients who underwent Auto-SCT for hematolog-
ical malignancies, were recruited at the Haematologic Departments of Campus Bio-Medico
and Tor Vergata University Hospitals. They were screened for complete laboratory assessment,
total-body computerized tomography scan (CT scan), virological pre-transplantation assess-
ment and for IL28B and IFNλ4 SNPs genotyping. Virological and bacterial infections were
recorded and evaluated up to 100 days following Auto-SCT. Antiviral prophylaxis with Acy-
clovir was administered immediately before the infusion and maintained for 1 year. CMV
reactivation by CMV DNAemia was evaluated once a week until day 100 from Auto-SCT. Pre-
emptive therapy with i.v. Ganciclovir (5mg/kg/12 hr) or i.v. Foscarnet (60 mg/kg/12hr) was
initiated either upon CMV DNAemia threshold level of 1000 IU/mL and/ or in presence of
organ disease (hepatic, pulmonary gastro-enteric) and discontinued after two consecutive
IL28B and IFNλ4 SNPs in CMV reactivation
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negative results. During episodes of active CMV infection, CMV surveillance was performed
twice a week, when possible.
Screening for hepatitis viruses
Antigen/antibodies screening for hepatitis viruses (A,B,C) was performed by Chemio Lumi-
nescent Immuno Assay (CLIA) using a sandwich test for antigen (HBsAg, HBeAg) or antibod-
ies (anti HCV, Anti HBsAg, Anti HBeAg, Anti HBcAg total and IgM) (Centaur, Siemens
Healthcare, Italy). HBV DNA and HCV RNA were performed by using COBAS Ampliprep
TaqMan48 according to the Manufacturer’s instructions (Roche, Italy).
Antibodies against CMV (IgG and IgM) were evaluate by Diasorin CLIA essay on LIAISON
XL Instruments (Diasorin, Italy).
Cytomegalovirus DNAemia
Cytomegalovirus DNA was extracted from plasma samples by versant KPCR Molecular Sys-
tem SP station and quantified by Real Time PCR assay in KPCR Molecular System AD (Sie-
mens Healthcare, Italy). The detection limit of the test is 200 IU/mL. Active CMV infection
was defined as the detection of CMV DNA in more than one plasma specimens. The duration
of a given episode of CMV DNAemia was considered to comprise the interval between the day
of first detection of CMV DNA in plasma and that of the first negative PCR results.
Single nucleotide polymorphism analysis
Genomic DNA was extracted from whole blood by using QIAamp DNA Mini Kit according to
the manufacturer’s instruction. The Rs12979860 IL28B SNP (C/T) genotype was determined
by Real Time PCR followed by Melting analysis (PCR Light Mix Kit IL28B -TIB MOLBIOL--
ROCHE, Italy) on DNA obtained as previously described. Genotyping for IFNλ4-TT/ΔG
(rs368234815) was performed with custom TaqMan allelic discrimination genotyping assays
on the LightCycler1 480 System (Roche, Basel, Switzerland). For quality control, blinded
duplicate specimens were included in the panel. Primers and probes were selected according
to previously report [10].
Statistical methods
Patients’ characteristics were summarized by means of frequency (n) and percentage (%) for
categorical variables or by means of median and range for continuous variables. Differences
among groups (IL28, CMV reactivation) were evaluated in univariate analysis by means of
non-parametric tests (Chi-Squared and Fisher Exact test in case of categorical variables,
Mann-Whitney and Kruskal-Wallis test in case of continuous variables) and logistic regression
model in multivariate analysis. Boxplots were used to show CMV copies at reactivation among
IL28B polymorphism levels. Survival CMV reactivation was estimated using the Kaplan-Meier
Product Limit estimator and the differences among groups were evaluated by means of Log-
Rank test. All tests were 2-sided, accepting P<0.05 as indicating a statistically significant differ-
ence and confidence intervals were calculated at 95% level. All analyses were performed using
the R software (R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-
0).
Results
Patients
Clinical and demographic data of the 99 patients are summarized in Table 1.
IL28B and IFNλ4 SNPs in CMV reactivation
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Multiple Myeloma (MM) patients were conditioned with Melphalan (200 mg, 140 mg or
100 mg) while subjects with Non Hodgkin Lymphoma received BEAM (#10) and Fotemustine
plus Etoposide, Cytarabine and Melphalan (FEAM #12). Before Auto-SCT, all patients
received viral screening as indicated in Table 2.
After Auto-SCT and until day 100 after the infusion, all patients were monitored for infec-
tive complications. CMV reactivation was observed in 34/99 (34%) patients, bacterial infec-
tions were detected in 32/99 patients (32%), while fungal infections were recorded in 1/99
(1%) patients. Because all 34 patients with active CMV DNAemia were positive for anti CMV
IgG, we refer to a reactivation of infection rather than a primary infection.
Among the patients with CMV reactivation, 13 had NHL and 21 MM, representing 59%
and 21% of the total NHL and MM patients respectively.
Polymorphism study
Genetic screening for IL-28B rs12979860 (C/T) and IFNλ4 rs368234815 (TT/ΔG) was per-
formed in all patients. As shown in Table 3, CC–TT/TT genotype was recorded in 46% of
Table 2. Pre-transplant viral screening.
Viral screening pre-Auto SCT (neg/pos)
HBsAg (neg/pos) 97/2
AntiHBs Ab 91/8
AntiHBc Ab 85/14
HBV DNA 98/1
AntiHCV Ab 99/0
HCV RNA 99/0
AntiCMV IgG (pos/neg) 77/22
Auto-Stem Cells transplantation
https://doi.org/10.1371/journal.pone.0200221.t002
Table 1. Baseline patients’ characteristics.
Number of patients 99
Median age (min-max) 56 (18–66)
Gender (M/F) 61/38
Disease
MM 77
NHL 82
Conditioning regimen
MEL 200 68
MEL 140 3
MEL 100 6
FEAM 12
BEAM 10
Median CD4+ infused value
CD4+/Kg (min-max) 5x106/Kg (2–11.2)
Engraftment (Days)
PMN >500/mmc 11 (3–83)
Ptls >20000/mmc 13 (9–41)
MM: Multiple Myeloma; NHL: Non Hodgkin Lymphoma; MEL: Melphalan (200 mg, 140 mg or 100 mg); BEAM:
Carmustine, Etoposide, Cytarabine and Melphalan FEAM: Fotemustine plus Etoposide, Cytarabine and Melphalan;
PML: Polymorphonucleate; Plts: Platelets.
https://doi.org/10.1371/journal.pone.0200221.t001
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patients while CT–TT/ΔG and TT -ΔG/ΔG was detected in 41% and 12% of the subjects,
respectively. Our analysis confirmed the strong Linkage Disequilibrium (LD) between these
two polymorphisms and the same T/ΔG minor allele frequency (MAF) of the Caucasian gen-
eral population (MAF 0.3).
Cytomegalovirus reactivation
Cytomegalovirus reactivation was found in 34/99 patients (34%). Fifty percent (6/12) of the
TT-ΔG/ΔG showed a CMV reactivation whereas, among patients bearing CC-TT/TT and
CT-TT/ΔG, 35% (16/46) and 29% (12/41), respectively, experienced CMV reactivation
(P = ns). As showed in Table 4, when the analysis was restricted in the setting of patients aged
>60 years (n = 30), CMV reactivation was significantly higher in patients with TT-ΔG/ΔG
genotype (83%) rather than in CT-TT/ΔG (40%) or in CC-TT/TT patients (21%) (P<0.05).
The analysis of median CMV DNA copies number at the reactivation was not significantly
correlated with a specific IL28B/IFNλ4 genotype, although higher levels of CMV DNAemia
were recorded in the heterozygote CT-TT/ΔG carriers when compared to the other groups
(Fig 1).
No difference was observed between Gangyclovir or Foscarnet as for treatment response to
antiviral treatment and disease recurrence by genetic polymorphisms.
Univariate and multivariate analysis
Univariate analysis highlighted that the presence of a diagnosis of NHL (P = 0.05), exposure to
immunotherapy with Rituximab (P = 0.0046), conditioning regimen with FEAM (P = 0.0058),
IgG positivity for CMV (P = 0.03) and the presence of bacterial infection (P = 0.045) were vari-
ables that significantly influenced CMV reactivation.
The monitoring of the CMV reactivation during 100 days post-transplantation by type of
conditioning regimen received, showed that patients receiving FEAM had an earlier (median
30 days) CMV reactivation (P = 0.0018) compared to those receiving BEAM (median not
reached, 65% reactivation) (Fig 2). Importantly, patients with MM who received high-dose
MEL as conditioning showed a lower incidence of reactivation compared to both BEAM and
FEAM regimen. Moreover, CMV reactivation was significantly higher within 60 days after
Auto-SCT in patients treated with Rituximab when compared to the group that did not (61%
vs 27.3% P<0.0034) (Fig 3).
Table 3. Genetic screening and polymorphisms of IL28B rs12979860 and IFNλ4 rs368234815.
IL28B
IFNλ4 CC CT TT
TT/TT 46(46%) 0 0
TT/ΔG 0 41(41%) 0
ΔG/ΔG 0 0 12(12%)
https://doi.org/10.1371/journal.pone.0200221.t003
Table 4. CMV reactivation and IL28B polymorphisms in patients aged>60 years.
IL28B/IFNλ4 CC-TT/TT CT-TT/ΔG TT-ΔG/ΔG P-value
total 14 10 6
CMV reactivation (%)
No 11 (78.6) 6 (60.0) 1 (16.7)
yes 3 (21.4) 4 (40.0) 5 (83.3) P<0.05
https://doi.org/10.1371/journal.pone.0200221.t004
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Multivariate analysis showed that only exposure with rituximab (P = 0.007) and the pres-
ence of CMV IgG significantly influenced CMV reactivation (P = 0.04).
Discussion
In recent years, gene-polymorphism studies have increased considerably. Scientific evidence
showed a very close link between the presence of defined polymorphisms in genes and their
involvement in the regulation and activation of innate and adaptive immune responses against
persistent viral infection like HCV or CMV. In this contest, the analysis of many polymor-
phism, such as CCR5 (chemokine receptor 5), MCP-1 (monocyte chemoattractant protein 1),
IL10 (interleukin 10), DC-SIGN (dendritic cell-specific molecule-3-grabbing non integrin),
highlighted a correlation between certain of these SNPs and an increased risk of CMV infec-
tion in patients who underwent Allo-SCT [19,20]. The rs12979860 (C/T) single nucleotide
polymorphism in IL28B gene region is well known to influence the spontaneous and treat-
ment-induced clearance in HCV infection [4–9]. In particular, the presence of the C allele and
the CC homozygosis has shown to guide positively the virus clearance. A strong Linkage dis-
equilibrium (LD) between IFNλ4-ΔG allele and the (unfavorable) IL28B rs12979860 T allele
Fig 1. CMV DNAemia at reactivation distributed between different IL28B/IFNλ4 genotypes.
https://doi.org/10.1371/journal.pone.0200221.g001
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was demonstrated to be very high in the Caucasians (>0.9) [10], meaning that variants are
always inherited together. The presence of ΔG allele is associated with the production of
IFNλ4 protein and with impaired HCV clearance. Due to the strong LD between the two
Fig 2. Kaplan Meier plot of CMV reactivation according to the type of conditioning chemotherapy regimen (BEAM vs. FEAM vs. MEL).
https://doi.org/10.1371/journal.pone.0200221.g002
Fig 3. Kaplan Meier plot of CMV reactivation according to Rituximab infusion received (yes vs. no).
https://doi.org/10.1371/journal.pone.0200221.g003
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SNPs, the rs12979860 T of IL-28B allele may act as a marker for IFNλ4 protein production.
Recently, a key role of the rs12979860 IL-28B SNP in the reactivation of some Herpesvirus and
CMV infection in the Allo-SCT setting was also suggested.
For example, the retrospective study of Bravo et al. [17], showed a trend towards a lower
incidence of active CMV infection in the TT genotype stem cell donors (even not statistically
significant). In the same time, the Egli’s group confirmed that solid organ transplant recipients
with a minor-allele genotype (TT) showed a trend to less CMV replication (CC vs TT, 52% vs
0%; P = 0.089) [1], suggesting a protective effect of the rs12979860 T allele against CMV infec-
tion and reactivation in immunocompromised patients.
By contrast, data from Manuel et al. [18] showed that solid transplanted patients, carrying
the IFNλ4 ΔG/ΔG genotype, have a higher but statistically not significant cumulative incidence
of CMV replication, compared with TT/TT or TT/ΔG carriers. In this study, the association
becomes statistically significant among patients followed by a preemptive approach, especially
in those receiving an organ from a seropositive donor but not among those who received anti-
viral prophylaxis [18].
The discordant results obtained by different groups in different transplantation setting
(Allo-SCT or solid organ), make very difficult to really understanding the clinical relevance of
such SNPs on CMV reactivation making further prospective studies necessary. Moreover, no
data, regarding the correlation between IL28B/IFNλ4 and CMV reactivation in Auto-SCT set-
ting, are available until now.
Our data suggest a significantly higher risk of CMV reactivation in NHL rather than in MM
and, among NHL patients, an increased risk of reactivation in subjects who received FEAM as
conditioning chemotherapy.
We also found that rituximab immunotherapy increased significantly the risk of CMV reacti-
vation respect to MM who did not receive Rituximab, probably due to its immunosuppressive
effect. The analysis of other risk factors showed no correlation between viral reactivation and dis-
ease-stage at transplantation or with the presence of antibody against HBV, HCV and HIV or pre-
vious exposition to proteasome inhibitors as also demonstrated by Marchesi and coworkers [21].
Interestingly, we noticed that the onset of bacterial infection was significantly related to
CMV reactivation in univariate but not into multivariate analysis, thus considering a bacterial
infection as a driver for CMV reactivation only in presence of other factors (i.e. immunosup-
pressive therapy).
The analysis of the correlation between IFNλ3 rs12979869 CT-TT/ΔG and IFNλ4 SNPs and
CMV reactivation showed that TT-ΔG/ΔG subjects reactivated more frequently (50%) than
CT-TT/ΔG (29%) or CC-TT/TT (35%) patients.
Considering only patients aged60 years, CMV reactivation was significantly higher in
TT-ΔG/ΔG genotype (83%) when compared to CT-TT/ΔG (40%) and CC-TT/TT (21%)
(P = 0.03). The achievement of statistical significance in this specific subgroup of our popula-
tion might be explained considering that the T/ΔG MAF rises from 0.3 to 0.4, rendering the
minor allele T/ΔG sufficiently represented.
Our results agree with what observed in HCV infection where, carrying TT-ΔG/ΔG geno-
type negatively influenced the clearance of infection but, significantly contrast with the evi-
dence of Bravo and Egli in Allo-SCT and solid transplantation setting, respectively [17,1]. On
the other hand, our data remark those obtained by Manuel et al. [18] who demonstrated a
highest cumulative incidence of CMV replication in ΔG/ΔG patients followed by a pre-emp-
tive approach in solid transplantation.
Even the results of these studies are hard to compare because they have been led using
patients managed in different setting of transplantation, the main differences may be explained
considering that in the Auto-SCT setting the donor/recipients are the same, leading to
IL28B and IFNλ4 SNPs in CMV reactivation
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consider only one type of immune system. By contrast, in Allo-SCT (but also in the solid trans-
plantation setting) we must take into account both the donor’s and the recipient’s immune sys-
tem, making the framework of interpretation more complex.
The exact mechanism by which these SNPs exert their activity is not well established.
Although the expression of IFNλ ligands seems to be modulate in both transcription factors bind-
ing and methylation sites of the promoter [22–24], the impact of such SNPs on IFNλ expression
is still debated. Some studies suggested that the presence of the “unfavorable” rs12979860 T allele
is associated with both reduced IFNλ3 expression and with higher and prolonged ISG expression,
especially in HCV infection [6–8, 25–31]. By contrast, the P70S aminoacid substitution in IFNλ4
protein has been shown to decrease IFN-related antiviral activity by the reduction of ISG expres-
sion levels [31]. Beside the relevance in controlling the innate immune signaling, an important
impact on adaptive immune function, such as virus-induced B cells proliferation, antibody pro-
duction and cytokines dysfunction, has also been proposed in acute infections [32– 33]. Thus, the
dual antiviral (by innate immunity) and immunomodulatory role of IL28B/IFNλ4 can result in
multiple possible interactions leading to a difficult and intriguing puzzle to resolve.
In conclusion, our study, which is the first performed in Auto-SCT setting, supports the
idea that the TT-ΔG/ΔG genotype is negatively involved in CMV reactivation and suggests
that TT-ΔG/ΔG patients aged60 years are at increased risk of CMV reactivation as well as
those with NHL or conditioned with FEAM.
The relatively low number of patients may limit our results and thus prospective and longer
studies in Auto-SCT transplant setting are needed to confirm and validate such findings.
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